IOB - Delayed Quote USD

Neurocrine Biosciences, Inc. (0K6R.IL)

146.03

+0.82

+(0.56%)

At close: July 23 at 9:00:00 PM GMT+1

Neurocrine Biosciences Announces New Survey Revealing Need for Routine Screening and Earlier Diagnosis for People Living with Tardive Dyskinesia

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the release of findings from a new survey conducted by The Harris Poll highlighting the profound negative impact of tardive dyskinesia on patients and reinforcing the need for routine screening, earlier diagnosis and treatment. The findings revealed that 80% of people living with tardive dyskinesia surveyed wished they had been screened for the condition earlier, and 86% wished their provider had discussed available treatment options fo

PR Newswire 5 hours ago

NBIX
Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 3 registrational program to evaluate the efficacy, safety and tolerability of NBI-1117568, the company's investigational oral muscarinic M4 selective orthosteric agonist, as a potential treatment for schizophrenia. Positive top-line data for the Phase 2 clinical study in adults with schizophrenia were reported in August 2024.

PR Newswire 5 days ago

NBIX
Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced publication of a post-hoc analysis from two 48-week studies, the KINECT® 3 extension and KINECT® 4, demonstrating the long-term safety profile and robust efficacy of INGREZZA® (valbenazine) capsules in adults aged 65 years and older with tardive dyskinesia (TD) in The Journal of Clinical Psychiatry. This represents the first and only published peer-reviewed analysis of a vesicular monoamine transporter 2 inhibitor for the treatment of T

PR Newswire 10 days ago

NBIX
Exploring 3 High Growth Tech Stocks In The US Market

Over the last 7 days, the United States market has experienced a 1.7% drop, but it has shown resilience with a 3.6% rise over the past year and an anticipated annual earnings growth of 13%. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for innovation and scalability in alignment with these positive long-term market trends.

Simply Wall St. 12 days ago

NBIX

BEIGF

ONC
With EPS Growth And More, Neurocrine Biosciences (NASDAQ:NBIX) Makes An Interesting Case

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Simply Wall St. 13 days ago

NBIX
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on May 5, 2025.

PR Newswire 20 days ago

NBIX
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Sanjay Keswani, M.D., to the company's executive management team as Chief Medical Officer (CMO) effective June 2, 2025. Dr. Keswani, an accomplished physician-scientist who has more than 20 years of pharmaceutical industry experience with broad R&D expertise in multiple therapeutic areas, will lead the clinical development and medical affairs activities at Neurocrine. Dr. Keswani succeeds Eiry W. Roberts, M.D., who ha

PR Newswire last month

NBIX
Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new data from a real-world study showing that all patients with tardive dyskinesia achieved a therapeutic dose with INGREZZA® (valbenazine) capsules upon initiation of treatment. This retrospective cohort study will be presented at the Academy of Managed Care Pharmacy 2025 Annual Meeting in Houston, Texas.

PR Newswire last month

NBIX
Exploring High Growth Tech Stocks in US for March 2025

Over the last 7 days, the United States market has risen by 1.8%, contributing to a 10% increase over the past year, with earnings projected to grow by 14% annually in the coming years. In this favorable environment, identifying high growth tech stocks involves focusing on companies that demonstrate strong innovation and scalability potential within this dynamic sector.

Simply Wall St. last month

ZETA

ORCL

NBIX
Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the long-term, open-label KINECT® 4 study demonstrating remission of tardive dyskinesia among the majority of patients treated with once-daily INGREZZA® (valbenazine) capsules. This analysis was presented at the 2025 Psychiatry Update Conference in Chicago.

PR Newswire last month

NBIX
Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from the KINECT®-HD study showcasing significant improvements in chorea across body regions with once-daily INGREZZA® (valbenazine) capsules in adults with Huntington's disease. The post-hoc analysis was presented at the Neuroscience Advanced Practice Provider Symposium hosted by the American Association of Neuroscience Nurses in New Orleans.

PR Newswire last month

NBIX
Big Pharma Walked Away From Mental Health. Why Some Are Coming Back.

Psychiatry was once big business for pharma, with drugs like Prozac making billions. Now a few breakthroughs are reviving interest.

The Wall Street Journal last month

ITCI

NBIX

BMY
Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18, 2025. Chief Executive Officer Kyle Gano and Chief Medical Officer Eiry Roberts will present at the conference.

PR Newswire last month

NBIX
Neurocrine Biosciences (NasdaqGS:NBIX) Begins Phase 1 Study Of New VMAT2 Inhibitor For Neurological Conditions

Neurocrine Biosciences (NasdaqGS:NBIX) announced the initiation of a Phase 1 clinical study for the compound NBI-1140675, a new VMAT2 inhibitor. This development could influence investor sentiment, though the company's stock experienced a 3% decline over the last week. This price movement may be linked to broader market concerns, such as the 2% drop in the tech-heavy Nasdaq Composite, driven by tariff uncertainties and volatile trading in tech stocks. While Neurocrine's broader portfolio and...

Simply Wall St. last month

NBIX
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of investigational compound NBI-1140675 in healthy adult participants. NBI-1140675 is an investigational, oral, selective second-generation small molecule inhibitor of the vesicular monoamine transporter 2 (VMAT2) in development for the potential treatment of certain neurological and neuropsychiatric conditions.

PR Newswire last month

NBIX
Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced top-line data from a Phase 4 study, KINECT-PRO™, demonstrating clinically meaningful and sustained effects of INGREZZA® (valbenazine) capsules on the physical, social and emotional impacts experienced by patients living with tardive dyskinesia (TD), irrespective of TD severity or underlying psychiatric condition. KINECT-PRO is the first study to show patient-reported impact of a vesicular monoamine transporter 2 inhibitor, specifically

PR Newswire 2 months ago

NBIX
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in March.

PR Newswire 2 months ago

NBIX
High Growth Tech Stocks To Watch In February 2025

Over the last 7 days, the United States market has dropped 2.2%, yet it remains up by 18% over the past year with earnings expected to grow by 14% per annum in the coming years. In this context, identifying high growth tech stocks involves looking for companies that can leverage technological advancements and maintain robust performance despite short-term market fluctuations.

Simply Wall St. 2 months ago

VRTX

NBIX

FIVN
Neurocrine Biosciences' (NASDAQ:NBIX) Performance Is Even Better Than Its Earnings Suggest

Even though Neurocrine Biosciences, Inc. ( NASDAQ:NBIX ) posted strong earnings, investors appeared to be underwhelmed...

Simply Wall St. 2 months ago

NBIX
Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine Biosciences may repurchase up to $500 million of its shares, subject to market conditions. This new share repurchase authorization is in addition to the $300 million accelerated repurchase program that was announced in October 2024 and completed in early February 2025.

PR Newswire 2 months ago

NBIX

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Neurocrine Biosciences, Inc. (0K6R.IL)

Neurocrine Biosciences Announces New Survey Revealing Need for Routine Screening and Earlier Diagnosis for People Living with Tardive Dyskinesia

Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia

Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry

Exploring 3 High Growth Tech Stocks In The US Market

With EPS Growth And More, Neurocrine Biosciences (NASDAQ:NBIX) Makes An Interesting Case

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results

Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer

Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia

Exploring High Growth Tech Stocks in US for March 2025

Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back.

Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum

Neurocrine Biosciences (NasdaqGS:NBIX) Begins Phase 1 Study Of New VMAT2 Inhibitor For Neurological Conditions

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures

Neurocrine Biosciences to Present at Upcoming Investor Conferences in March

High Growth Tech Stocks To Watch In February 2025

Neurocrine Biosciences' (NASDAQ:NBIX) Performance Is Even Better Than Its Earnings Suggest

Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program